Tibolone Endometrium Study (Study 32972)(P06470)

• Status: Completed
• Trial end date: 2005-07-21

Summary

Tibolone has been registered for the treatment of climacteric symptoms and for the prevention of postmenopausal osteoporosis. This is a 2-year study to further confirm the endometrial safety of tibolone in comparison with CE/MPA.

• Phase: Phase 3

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Medroxyprogesterone; Medroxyprogesterone Acetate; Tibolone